Explain in detail biosynthesis and catabolism of catecholamine

Reading File

Finding Sources

Searching Images

catecholamine biosynthesis pathway dopamine norepinephrine epinephrine

Reading File

Finding Sources

Reading File

Loading Image

Reading File

Searching Images

catecholamine degradation MAO COMT VMA vanillylmandelic acid pathway

Reading File

Finding Sources

Reading File

Loading Image

I now have all the information needed for a comprehensive, detailed answer. Let me compile it.

Biosynthesis and Catabolism of Catecholamines

Overview

The catecholamines — dopamine, norepinephrine (NE), and epinephrine (Epi) — share a common structural motif: a catechol ring (ortho-dihydroxybenzene) plus an ethylamine side chain. They are synthesized from the amino acid tyrosine through a sequential enzymatic cascade, and degraded primarily by two enzymes — monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).

Part I: Biosynthesis

Biosynthetic pathway diagram:

Catecholamine biosynthesis pathway from tyrosine to epinephrine

The conversion of tyrosine to epinephrine requires four sequential enzymatic steps.

Step 1 — Tyrosine → L-DOPA

Enzyme: Tyrosine hydroxylase (TH) Location: Cytosol of catecholamine-producing neurons and adrenal chromaffin cells Cofactor: Tetrahydrobiopterin (BH₄), molecular O₂, Fe²⁺ Reaction: Hydroxylation of the para-position of the phenyl ring of tyrosine → 3,4-dihydroxyphenylalanine (L-DOPA)

This is the rate-limiting step. TH is subject to feedback inhibition by dopamine and norepinephrine, which compete with the BH₄ cofactor — providing tight internal regulation of catecholamine output. Tyrosine is transported into neurons via a Na⁺-dependent carrier. Some tyrosine is derived from dietary phenylalanine via phenylalanine hydroxylase in the liver, but most is of dietary origin directly.

Clinically: α-methyl-p-tyrosine (metyrosine) competitively inhibits TH and is used to reduce catecholamine synthesis in patients with pheochromocytoma. Catecholamines cannot cross the blood–brain barrier, so they must be synthesized locally in the CNS. L-DOPA does cross the blood–brain barrier, which is the basis for its use in Parkinson disease. — Harper's Illustrated Biochemistry, 32nd Ed; Goldman-Cecil Medicine

Step 2 — L-DOPA → Dopamine

Enzyme: Aromatic L-amino acid decarboxylase (AADC), also called dopa decarboxylase Location: Cytosol; present in virtually all tissues Cofactor: Pyridoxal phosphate (vitamin B₆) Reaction: Decarboxylation of L-DOPA → 3,4-dihydroxyphenylethylamine (dopamine)

This enzyme is widely expressed and not tissue-specific. Dopamine neurons express TH + AADC but lack DBH (the next enzyme), so dopamine is their final product. Competitive inhibitors (e.g., α-methyldopa) are effective antihypertensives. Carbidopa, a peripheral AADC inhibitor that does not cross the BBB, is co-administered with L-DOPA to reduce peripheral side effects. — Harper's Illustrated Biochemistry; Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Step 3 — Dopamine → Norepinephrine

Enzyme: Dopamine β-hydroxylase (DBH) Location: Inside secretory/storage vesicles (granule-bound enzyme) — the only transmitter synthesized inside a vesicle Cofactors: Ascorbate (electron donor), Cu²⁺ at the active site, fumarate as modulator Reaction: β-hydroxylation of dopamine's side chain → norepinephrine

After synthesis in the cytoplasm, dopamine is actively transported into the vesicle by the vesicular monoamine transporter (VMAT), driven by a H⁺ gradient. DBH then converts it to NE inside the vesicle. DBH is a monooxygenase. Reserpine blocks VMAT and depletes catecholamine stores. — Ganong's Review of Medical Physiology, 26th Ed; Harper's Illustrated Biochemistry

Step 4 — Norepinephrine → Epinephrine

Enzyme: Phenylethanolamine N-methyltransferase (PNMT) Location: Cytoplasm of adrenal medullary chromaffin cells and organ of Zuckerkandl; absent from most peripheral sympathetic neurons Methyl donor: S-adenosylmethionine (SAM) Reaction: N-methylation of norepinephrine → epinephrine

Because PNMT is a cytoplasmic enzyme, NE must exit the storage vesicle into the cytoplasm for methylation, then re-enter a separate vesicle. PNMT expression is induced by glucocorticoids delivered via the unique intra-adrenal portal system, which creates a ~100-fold steroid concentration gradient over systemic levels. This is why adrenal medullary tissue produces ~80% epinephrine, while extra-adrenal paragangliomas, which lack this high cortisol exposure, synthesize primarily norepinephrine. — Goldman-Cecil Medicine; Sabiston Textbook of Surgery

Noradrenergic synapse showing biosynthetic and release machinery:

Biochemical events at a noradrenergic synapse including synthesis, storage, release, and reuptake of NE

Summary Table: Biosynthetic Enzymes

Step	Substrate	Product	Enzyme	Location	Cofactor
1 (rate-limiting)	Tyrosine	L-DOPA	Tyrosine hydroxylase	Cytosol	BH₄, O₂, Fe²⁺
2	L-DOPA	Dopamine	Dopa decarboxylase (AADC)	Cytosol	Pyridoxal-P (B₆)
3	Dopamine	Norepinephrine	Dopamine β-hydroxylase	Vesicle lumen	Ascorbate, Cu²⁺
4	Norepinephrine	Epinephrine	PNMT	Cytosol (adrenal only)	SAM

Part II: Storage and Release

Catecholamines are stored in chromaffin granules (adrenal medulla) or synaptic vesicles (neurons), co-packaged with ATP, chromogranins, and neuropeptides. Release occurs by Ca²⁺-dependent exocytosis triggered by action potentials. The process involves SNAPs and VAMPs (vesicle-associated membrane proteins). Sympathetic stimulation can increase adrenal catecholamine secretion up to 50-fold above basal levels. — Sabiston Textbook of Surgery

Part III: Catabolism

Catecholamines are potent but short-lived: plasma half-life is 10–100 seconds, with NE/Epi having a half-life on the order of ~1 minute. Inactivation occurs through three mechanisms:

Reuptake (dominant mechanism)
Enzymatic degradation (MAO and COMT)
Diffusion away from the synapse

3.1 Reuptake

Almost 90% of NE released at sympathetic synapses is removed by Uptake 1 (neuronal reuptake) via the norepinephrine transporter (NET). This is blocked by cocaine, tricyclic antidepressants, and phenothiazines. Extraneuronal tissues also take up catecholamines via Uptake 2, where most are metabolized by COMT. — Goldman-Cecil Medicine

3.2 Enzymatic Degradation: The Two Key Enzymes

Monoamine Oxidase (MAO)

Location: Outer mitochondrial membrane; present in nerve terminals, liver, gut wall, and many other tissues
Reaction: Oxidative deamination of the amine side chain → reactive aldehyde intermediate
Subtypes: MAO-A (preferentially deaminates NE, Epi, serotonin); MAO-B (preferentially deaminates dopamine, phenylethylamine)
The aldehyde intermediate from dopamine is further oxidized by aldehyde dehydrogenase → DOPAC (3,4-dihydroxyphenylacetic acid)
The aldehyde intermediate from NE and Epi (β-hydroxylated) is preferentially reduced by aldehyde reductase → DHPG (3,4-dihydroxyphenylglycol)
MAO inhibitors (MAOIs) (e.g., phenelzine, selegiline) are used as antidepressants and in Parkinson disease

Catechol-O-Methyltransferase (COMT)

Location: Cytoplasm and membranes of most extraneuronal tissues — liver, kidney, smooth muscle, glial cells; absent from presynaptic noradrenergic neurons
Reaction: O-methylation (meta-position) using SAM as methyl donor
Converts: NE → normetanephrine; Epi → metanephrine; dopamine → methoxytyramine
COMT inhibitors (e.g., tolcapone, entacapone) are used adjunctively in Parkinson disease

3.3 Detailed Catabolic Pathways

Simplified catabolism diagram (Lippincott):

Catecholamine catabolism — epinephrine and norepinephrine to vanillylmandelic acid via MAO and COMT

Comprehensive catabolism pathway diagram (Tietz):

Detailed pathways of catecholamine metabolism showing dopamine, norepinephrine, and epinephrine catabolism via MAO, COMT, AD, AR to HVA, VMA, and MHPG

Pathway A — NE/Epi: COMT First, Then MAO

Most important for extraneuronal (circulating) catecholamines

COMT acts: NE → normetanephrine; Epi → metanephrine (collectively called metanephrines)
MAO acts on these O-methylated intermediates → reactive aldehydes → converted by aldehyde dehydrogenase → vanillylmandelic acid (VMA)

Pathway B — NE/Epi: MAO First, Then COMT

Most important for neuronal (intraneuronal) catecholamines leaking from storage vesicles

MAO acts intraneuronally on NE/Epi → aldehyde intermediate → reduced by aldehyde reductase → DHPG (3,4-dihydroxyphenylglycol)
COMT then O-methylates DHPG → MHPG (3-methoxy-4-hydroxyphenylglycol)
MHPG can be further oxidized by aldehyde dehydrogenase → VMA

VMA (vanillylmandelic acid) is the major final urinary metabolite of NE and Epi. — Ganong's; Goldman-Cecil

Dopamine Catabolism

Dopamine follows a parallel pathway:

MAO → DOPAC (3,4-dihydroxyphenylacetic acid) — via aldehyde dehydrogenase
COMT acts on dopamine → methoxytyramine
Sequential action of both enzymes ultimately yields homovanillic acid (HVA) as the major terminal metabolite of dopamine

3.4 Final Excretion

Major urinary metabolites: VMA (NE, Epi), HVA (dopamine), MHPG (neuronal NE)
Metanephrines (metanephrine and normetanephrine) are also measurable in plasma and urine
Further conjugation with sulfate (SULT1A3) or glucuronic acid in the liver before renal excretion
Because metanephrines have relatively stable plasma levels (unlike the pulsatile NE/Epi), plasma free metanephrines are the preferred screening test for pheochromocytoma — Sabiston Textbook of Surgery

Summary of Major Metabolites

Catecholamine	Neuronal Pathway (MAO first)	Extraneuronal Pathway (COMT first)	Final Major Metabolite
Norepinephrine	NE → DHPG → MHPG → VMA	NE → Normetanephrine → VMA	VMA
Epinephrine	Epi → DHPG → MHPG → VMA	Epi → Metanephrine → VMA	VMA
Dopamine	DA → DOPAC → HVA	DA → Methoxytyramine → HVA	HVA

Part IV: Pharmacological and Clinical Correlations

Drug/Condition	Mechanism	Effect
Metyrosine	TH inhibitor	Reduces catecholamine synthesis (used in pheo)
Carbidopa	AADC inhibitor (peripheral)	Prevents peripheral L-DOPA conversion
Reserpine	VMAT blocker	Depletes catecholamine stores → antihypertensive
Cocaine, TCAs	NET/DAT blocker	Prolongs catecholamine action
MAOIs	MAO inhibition	↑ NE, DA, 5-HT — antidepressant
Entacapone/Tolcapone	COMT inhibitor	Prolongs L-DOPA action in Parkinson
Pheochromocytoma	Excess NE/Epi secretion	Diagnosed by plasma/urine metanephrines and VMA
Parkinson disease	Dopamine deficiency (substantia nigra)	Treated with L-DOPA + carbidopa

Sources: Harper's Illustrated Biochemistry, 32nd Ed | Ganong's Review of Medical Physiology, 26th Ed | Goldman-Cecil Medicine | Sabiston Textbook of Surgery | Kaplan & Sadock's Comprehensive Textbook of Psychiatry | Tietz Textbook of Laboratory Medicine, 7th Ed | Lippincott's Illustrated Reviews: Biochemistry, 8th Ed

This is a shared conversation. Sign in to Orris to start your own chat.